Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cosmos Health Inc. filings document the public-company record of a Nevada healthcare issuer with common stock listed on the Nasdaq Capital Market under COSM. Recent Form 8-K reports cover operating results, Regulation FD disclosures, Nasdaq minimum-bid-price compliance matters, board appointments, annual-meeting voting results and capital-structure proposals involving common stock and blank-check preferred stock.
The filing record also includes a Form 12b-25 notice for a delayed annual report and disclosures tied to business performance across contract manufacturing, wholesale distribution, proprietary nutraceutical brands and research and development. These documents address governance, listing status, share authorization, financial reporting timing and the company's operating subsidiaries and product portfolio.
Cosmos Health Inc. insider filing shows its CEO and 10% owner, Grigorios Siokas, acquiring 113,185 shares of common stock on January 12, 2026. The shares were obtained at $0.5036 per share under a Debt Exchange Agreement, using $57,000 of debt the company owed to him as payment instead of cash. After this transaction, he beneficially owns 7,244,979 common shares directly.
Cosmos Health Inc. insider transaction: Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired 156,190 shares of Common Stock on January 8, 2026. The shares were obtained at $0.5186 per share pursuant to a Debt Exchange Agreement, in which $81,000 of debt that the company owed to Mr. Siokas was exchanged for stock at the fair market value on that date. Following this transaction, he beneficially owned 7,131,794 shares of Common Stock, held directly.
Cosmos Health Inc. director, chief executive officer, and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On January 7, 2026, he acquired 124,880 shares of common stock at $0.5205 per share, identified as Exchange Shares under a Debt Exchange Agreement with the company. The shares were issued in exchange for $65,000 of debt the company owed to him, effectively converting that obligation into equity rather than a cash payment. Following this transaction, he beneficially owned 6,975,604 shares of the company’s common stock, held directly.
Cosmos Health Inc. CEO Grigorios Siokas acquired 133,953 common shares at $0.5375 per share on January 6, 2026. The shares were issued under a Debt Exchange Agreement in which $72,000 of debt the company owed to Mr. Siokas was exchanged for stock at the fair market value of the common shares on that date.
After this transaction, Mr. Siokas beneficially owned 6,850,724 shares of Cosmos Health common stock in direct ownership. He is reported as a director, chief executive officer, and a 10% owner of the company.
COSMOS HEALTH INC. reported that Nasdaq notified the company on December 11, 2025 that it is not in compliance with the Nasdaq Listing Rule requiring a minimum bid price of $1.00 per share for 30 consecutive business days. The company now has 180 calendar days from December 11, 2025 to regain compliance by keeping its common stock closing bid price at or above $1.00 per share for at least 10 consecutive business days.
If the company does not otherwise regain compliance with this listing standard, it states that it intends to implement a reverse stock split to meet the rule. Nasdaq will also display an indicator with quotation information related to the company’s securities, signaling the current non-compliance status to the market.
Cosmos Health Inc. CEO Grigorios Siokas converted $70,000 of company debt into 168,472 shares of common stock on December 15, 2025. The shares, described as Exchange Shares under a Debt Exchange Agreement between Siokas and the company, were issued at $0.4155 per share, identified as the fair market value of the stock on that date.
After this transaction, Siokas directly beneficially owned 6,628,457 Cosmos Health common shares. He is listed as a director, chief executive officer, and a more than 10% owner of Cosmos Health Inc.
Cosmos Health Inc. (COSM) reported an insider transaction by Chief Executive Officer, director and 10% owner Grigorios Siokas. On 11/25/2025, Mr. Siokas acquired 55,732 shares of common stock at $0.628 per share through a debt-for-equity exchange.
Under a Debt Exchange Agreement between Mr. Siokas and the company, these Exchange Shares were issued in exchange for $35,000 of debt that Cosmos Health owed to him. Following this transaction, Mr. Siokas beneficially owns 6,383,625 shares of Cosmos Health common stock, held in direct ownership.
Cosmos Health Inc. (COSM) CEO, director and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On 11/21/2025, he acquired 56,080 shares of common stock at $0.6776 per share, identified as Exchange Shares under a Debt Exchange Agreement between him and the company. The price reflects the fair market value of the stock on that date and was used to exchange $38,000 of debt the company owed to him. Following this transaction, he beneficially owned 6,327,893 shares of Cosmos Health common stock, held directly.
Cosmos Health Inc. (COSM) insider Grigorios Siokas increased his stake through a debt-for-equity exchange. On 11/20/2025, the CEO, director and 10% owner acquired 51,315 shares of common stock at $0.6236 per share. The shares were issued as "Exchange Shares" in satisfaction of $32,000 that the company owed to him under a debt exchange agreement, using the fair market value of the stock on that date.
After this transaction, Siokas beneficially owned 6,271,813 shares held directly. This was a non-cash transaction for the company, converting a payable to equity while increasing the CEO’s direct ownership.
Cosmos Health Inc. (COSM) disclosed that its Chief Executive Officer, director and 10% owner, Grigorios Siokas, acquired additional common shares through a debt-for-equity exchange. On November 19, 2025, he acquired 61,614 shares of common stock at $0.6492 per share, described as the fair market value of the stock on that date. The shares were issued in exchange for a total of $40,000 that the company owed to Mr. Siokas under a debt exchange agreement. Following this transaction, he beneficially owns 6,220,498 common shares directly.